Carlsmed, Inc. (CARL) stock analysis
Healthcare · Health Information Services
From the 10-K filed 2026-02-25
How it makes money
It earns revenue by selling personalized interbody implants and surgical kits to hospitals and surgical centers for spine fusion procedures.
It provides surgeons with AI-generated surgical plans and custom-fit implants, replacing traditional 'stock' implants that come in pre-defined sizes. Revenue scales as it secures adoption for its aprevo platform in both lumbar and cervical fusion markets, with profitability driven by the ability to reduce costly revision surgeries for patients.
What protects it: the moat
Its competitive protection rests on proprietary AI algorithms and FDA Breakthrough Device designations, though it remains a new entrant in a crowded market.
Management asserts that its digital technology platform and personalized manufacturing process address specific limitations of traditional, symmetric implants. However, it operates in a highly competitive industry where new developments by established players could render its technology obsolete.
What growth costs
It incurs significant costs to manage an on-demand, customized manufacturing model and to fund the ongoing commercial expansion of its platform.
Growth requires investment in a direct sales force to drive adoption among surgeons and in the digital production systems necessary to meet short lead-time delivery requirements. It relies on third-party contract manufacturers, creating ongoing operational expenses tied to supply chain management and product sterilization.
What could damage it
The loss of third-party payor coverage would impair its business by removing the mechanism that funds the purchase of its personalized implants.
Since the value proposition relies on reducing long-term economic burdens through lower revision rates, a refusal by insurers to provide adequate reimbursement would force hospitals to revert to cheaper, traditional stock implants, effectively destroying the primary market for its custom technology.
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.